- Eli Lilly (NYSE:LLY) reported new Omvoh data showing corticosteroid-free disease control in ulcerative colitis patients with prior biologic failure.
- The same readout indicated deep remission outcomes in Crohn's disease, including in individuals who had not responded to earlier biologic drugs.
- Researchers highlighted multi-dimensional benefits that covered symptom control and quality-of-life measures for inflammatory bowel disease patients in the trials.
- These Omvoh ulcerative colitis and Crohn's disease results deserve to be weighed alongside the rest of our Eli Lilly view. We have also flagged 1 warning sign for Eli Lilly.
This kind of immunology progress is not unique to Eli Lilly, so it is worth comparing across peers via 34 healthcare AI stocks.
Eli Lilly is a US pharmaceuticals group that discovers and sells human medicines globally, and Omvoh sits within its immunology franchise that targets chronic inflammatory conditions. For this readout, the focus is on how its pipeline is being applied to inflammatory bowel disease.
3 things going right for Eli Lilly that this headline doesn't cover.
How does this Omvoh readout change the ulcerative colitis and Crohn's treatment picture?
The new one year data show 27.7% of ulcerative colitis patients on Omvoh achieved comprehensive disease control versus 14% on placebo, with 23.4% vs 9.4% in the prior biologic failure subgroup. In Crohn's disease, 20.4% on Omvoh reached corticosteroid free deep remission compared with 2% on placebo, and 15.7% vs 0% in those who had failed previous biologics. That underlines Omvoh’s reach into harder to treat inflammatory bowel disease populations.
Does this change the Eli Lilly Narrative investors have been using?
The Narrative already leans on Eli Lilly broadening revenue beyond incretin obesity and diabetes drugs into areas like immunology and oncology. Omvoh data that connect composite endpoints with quality of life measures such as IBDQ remission reinforce that non incretin franchises can contribute meaningful, high value indications alongside Mounjaro, Zepbound and Foundayo. It supports the idea of a more diversified earnings mix over time, even as pricing and legal risks around GLP 1s remain key watchpoints.
See how these catalysts shape Eli Lilly's path to a $1,329 fair value.
What should investors watch next from this Omvoh program?
The near term marker to track is how clinicians and guidelines react after the LUCENT and VIVID post hoc analyses are presented at UEG Week 2026 and then digested in practice. Watch for any future updates from Eli Lilly that quantify Omvoh prescription trends in ulcerative colitis and Crohn's disease, particularly use in patients with prior biologic failure, because that segment is explicitly highlighted in these results.
Add Eli Lilly to your Watchlist and get alerts as these catalysts play out.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com